6 results about "Leukemia lymphoma" patented technology

Antibodies, fragments thereof and fusion proteins that specifically bind to Clec12A, are described, as well as methods of making and using such antibodies. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various autoimmune diseases and cancers, including leukemia, lymphoma, or myeloma, including, for example, acute myeloid leukemia.

The application discloses a D-A-D type organic small molecule, nanoparticles containing the same, and a preparation method and application thereof. The D-A-D type organic small molecule and the nanoparticles thereof are particularly suitable for precise photothermal treatment and real-time imaging guidance of hematological malignancies such as leukemia, lymphoma and multiple myeloma. The D-A-D type organic small molecule constructs a D-A-D type conjugated structure, realizes near-infrared absorption red shift to 685 nm through enhancing intramolecular charge transfer (ICT) effect, and promotes non-radiative transition by using high excited state reorganization energy (lambda=1.29eV), with a photothermal conversion efficiency of more than 35%. The small molecule does not contain metal and halogen, has a molecular weight of about 878 Da, and has good biocompatibility and metabolic potential. The small molecule is self-assembled into nanoparticles with a particle size of about 130 nm, and has good colloidal stability and passive targeting ability. Meanwhile, the high molar absorption coefficient and high-efficiency photothermal conversion characteristics of the small molecule endow the small molecule with strong photoacoustic imaging capability, and the small molecule can be used for real-time monitoring of drug distribution and realization of 'diagnosis and treatment integration'.

This invention discloses a predictive model for assessing the risk of severe cytokine release syndrome (SCR) in patients with hematologic malignancies after CAR-T cell therapy. The model includes a nomogram and a prognostic risk scoring formula to assess the risk of SCR after CAR-T cell infusion. The biomarkers are the peripheral blood cytokine concentrations during 24-48 hours after CAR-T cell infusion, including five cytokines: CX3CL1, GZMB, IL4, IL6, and PDGFAA. The nomogram in this invention is the first predictive model established applicable to assessing the risk of SCR in patients with leukemia, lymphoma, and multiple myeloma undergoing CAR-T cell therapy. The model is simple, intuitive, and easy to implement, effectively helping clinicians assess the risk of SCR after CAR-T cell therapy, thus providing theoretical guidance for patient monitoring and treatment.

The present invention provides novel compounds of Formula (I), (II), or (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and / or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., CDK7, CDK12, or CDK13), and therefore, induce cellular apoptosis and / or inhibit transcription in the subject.

The disclosure herein provides combination therapies for the treatment of cancers such as Leukemia, lymphoma and triple negative breast cancer. The disclosure provides combination therapies of CDK inhibitors, e.g., a CDK inhibitor represented by Formula I:or a pharmaceutically acceptable salt thereof together with a BCL-2 inhibitor or proteasome inhibitor for the treatment of cancer.

The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.